Data from the CHECKMATE-817 trial demonstrated that the combination of nivolumab and ipilimumab is a safe first-line treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who also harbour comorbidities or a poor Eastern Cooperative Oncology Group (ECOG) performance status. The combination was shown to have a consistent safety profile in these special populations.
Until recently, data on immunotherapy in patients with advanced NSCLC and poor performance status or other comorbidities were limited. CheckMate 817 –a multi-cohort, open-label phase 3b/4 study– investigated safety and efficacy of flat-dose nivolumab + weight-based low-dose ipilimumab in patients with advanced NSCLC. Dr Fabrice Barlesi (Hôpitaux de Marseille, France) evaluated this regimen as first-line treatment in a reference population (cohort A, n=391, ECOG performance status 0-1) and a special population (cohort A1, n=198) consisting of patients with ECOG performance ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Novel ways to assess MS Next Article
Risk of hypogammaglobulinemia and rituximab »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.